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Spinal muscular atrophy (SMA) is the leading cause of infant mortality, it is the second most 
common autosomal recessive heritable neurodegenerative disease, after cystic fibrosis. SMA 
is characterized by α motor neuron loss in the anterior horn of the spinal cord and lower 
brainstem, progressive muscle weakness and atrophy [1-2]. SMA is caused by the absence of the 
gene SMN1 and the mutation of the gene SMN2. That mutation produces a change of one 
nucleotide in SMN2, creating an exon splicing silencer element, whose mRNA transcripts 
produce around 90% of a truncated and unstable form of survival motor neuron (SMN) protein 
that is rapidly degraded. Several small molecules and repurposed drugs were tested for an 
increase in the concentration of SMN in a high throughput screening using an SMN2 luciferase 
reporter assay resulting in the hit compound LDN-75654 (EC50 = 1.8 μM, 242 %, plasma 
stability = 13 minutes) (Scheme 1). A structure-activity relationship (SAR) study was 
conducted to increase the pharmacokinetic properties, potency and plasma stability outcoming 
in the lead compound LDN-27 (EC50 = 0.29 μM, 190 %, plasma stability = 326 minutes), 
whose mechanism of action is by stabilizing the SMN protein post-translationally [3].  
 
 
Scheme 1 Previous optimization results 
 
New analogues of the lead compound have been developed by introducing an imidazole ring 
as the heterocycle core in order to further study how the effect on the SMN concentration as 
well as solubility and potency properties are influenced (Scheme 2). 
 
 




































AlPO4  Aluminium phosphate   
ASO  Antisense oligonucleotides  
BBr3  Boron tribromide 
C  Cytosine  
cDNA  Complementary deoxyribonucleic acid 
CO2  Carbon dioxide  
CoSO4 7 H2O Cobalt(II) sulphate heptahydrate 
Cs2CO3 Caesium carbonate  
DBH  1,3-Dibromo-5,5-dimethylhydantoin 
DCH  1,3-Dichloro-5,5-dimethylhydantoin 
DCM  Dichloromethane    
DIH  1,3-Diiodo-5,5-dimethylhydantoin 
DMF  N,N-Dimethylformamide 
EDC   1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EI  Electron ionization  
EtOAc  Ethyl acetate 
ESI  Electrospray ionization  
Et3N  Triethylamine  
GC-MS Gas chromatography mass spectroscopy  
H2  Hydrogen gas 
HCl  Hydrochloric acid 
HI  Hydroiodic acid 
HOAt   1-Hydroxy-7-azabenzotriazole 
H2O  Water  
HPLC  High performance liquid chromatography  
H2SO4  Sulfuric acid 
HTS  High-throughput screening  
I2  Iodine 
K2CO3  Potassium carbonate  
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KI  Potassium iodide  
KOH  Potassium hydroxide  
K2SO3  Potassium sulphite 
LC-MS Liquid chromatography mass spectroscopy 
LDDN  Laboratory for Drug Discovery in Neurodegeneration  
LiAlH4 Lithium aluminium hydride 
Me3Al  Trimethylaluminum  
Mg  Magnesium  
MeI  Methyl iodide 
MeOH  Methanol 
MHz  Megahertz 
mRNA  Messenger ribonucleic acid 
N2  Nitrogen gas 
NaBH4  Sodium borohydride 
NaCl  Sodium chloride 
NaH  Sodium hydride  
NaOH  Sodium hydroxide 
NaSO3  Sodium sulphite  
Na2SO4 Sodium sulphate  
n-BuLi  n-Butyl lithium  
NH4Cl  Ammonium chloride 
NMR  Nuclear magnetic resonance 
ON   Overnight  
Pd(OH)2/C Palladium hydroxide on activated charcoal 
PET   Positron emission tomography   
ppm  Parts per million  
Py  Pyridine 
RT  Room temperature  
SAR  Structure activity relationship 
SMA  Spinal muscular atrophy 
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SMN  Survival motor neuron 
snRNPs Small nuclear ribonucleoproteins 
SOCl2  Thionyl chloride  
T  Thymine 
t ½  Half life 
THF  Tetrahydrofuran 
UV  Ultraviolet  
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1.1 Spinal Muscular Atrophy  
 
Spinal muscular atrophy (SMA) is a serious heritable, autosomal recessive, neurodegenerative 
disease characterized by motor neuron loss in the anterior horn of the spinal cord and lower 
brainstem, muscle weakness and atrophy. It is one of the leading causes of infant mortality in 
the world, being the most common cause of mortality for children under the age of two, 
occurring in 1 in 30 154 to 1 in 36 012 live births, with a carrier frequency of 1 in 76 to 1 in 
1111. 
 
SMA is caused by homozygous mutation of SMN1 gene that encodes for the survival motor 
neuron (SMN) protein. Duplication at chromosome 5q11-q13, which contains two almost 
identical genes, SMN1 telomeric and SMN2 centromeric (Figure 1), an exchange of C to a T 
nucleotide in exon 7 of SMN2 creates an exon splicing silencer element. Due to this, mutation 
exon 7 is excluded from the majority of SMN2 mRNA transcripts (SMN∆7)2-3, producing a 
truncated and unstable form of the SMN protein that is rapidly degraded. 
SMN protein along with eight other core protein components, forms the named SMN complex, 
whose best described function is the assembly of small nuclear ribonucleoproteins (snRNPs) 
of spliceosomes, that are essential components for the splicing of RNA4-5 in all tissues. 
 However, a small fraction of SMN2 transcripts include exon 7, which produces the full length 
SMN and provides enough SMN to avoid lethality but not enough to compensate for the loss 
of SMN1 and to result in motor neuron diseases, such as SMA. 
Typically, healthy individuals carry two copies of SMN1 gene and one-to-two copies of SMN2 
gene, which are unaffected. For SMA patients, the number of copies of the SMN2 gene and 
the severity of the condition have an inverse correlation; the more copies of SMN2 gene that 
exist, the more full-length SMN protein that is produced and the severity of the disease is 
reduced.  
SMA has five different subtypes based on the age of onset as well as based on the number of 
copies of the SMN2 gene present6-8. Type 0, also known as prenatal SMA, typically is fatal in 
utero or few first months of age and is predicted to have only one copy of SMN29. Type I SMA, 
also referred as Werdnig-Hoffman, is the most common type of SMA with two copies of 
SMN2; these babies show signs of the disease around 6 months after birth, when they are 
unable to sit unassisted. Type I patients typically do not survive past 2 years of age.  
 
Type II SMA, also called intermediate form, has three copies of SMN2. Afflicted babies, 
typically are affected before 18 months of age, when they are able to sit unassisted but are 
unable to stand. Type III SMA, also referred as Kugelberg-Welander disease, has three or four 
copies of SMN2; these patients show symptoms after 2 years of age. Type IV SMA, with more 
than four copies of SMN2, manifests with mild proximal muscle weakness, and patients 








Figure 1 SMN genes 
 
1.2 Therapeutic Strategies 
 
Currently, several different therapeutic strategies10 are being developed, the most interesting 
of which focus on SMN2, due to the inverse correlation between the number of copies of SMN2 
and the severity of the disease. The possible pathways to slow the progression of the disease 
include increasing the transcription of SMN2, promoting the inclusion of exon 7 during the 
transcription, as well as stabilizing the SMN protein. 
Another approach is using gene therapy to include a viral vector containing SMN1 to SMA 
mice. However, for gene therapy to work, the viral vector must be delivered to the correct cells 
after passing the blood-brain-barrier. The possibility of the immune system reacting to the 
introduction of the viral vector and the integration of the gene into the host genome are some 
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other potential problems for this strategy. For SMA, the viral vector used is self-complementary 
adeno associated virus 9 (scAAV9). 
Another therapeutic strategy is the use of antisense oligonucleotides (ASO) designed to 
specifically target and inactivate the splicing silencer in order to include exon 7 and to increase 
the amount of protein. Spinraza, the first and only approved treatment for this illness, follows 
this mechanism of action. 
 
1.3 Previous Work on Small molecules  
 
A high-throughput screening (HTS) of small molecules, including repurposed drug11, was 
tested on a cell based SMN2 reporter assay to identify the increase the SMN protein 
independently of the SMN2 translation. The cell-based reporter assay12 contains luciferase that 
combines a SMN2 promoter, SMN exons 1-6 cDNA, followed by the splicing cassette 
containing intron 6, exon 7, intron 7 and exon 8. The terminal codon of exon was modified so, 
when spliced into exon 8, the SMN-firefly luciferase is in frame and can be detected. This was 
developed and used for the testing of repurposed drugs and small molecules for the increase 
the concentration of SMN protein.  
LDN-75654 (Figure 2) is the hit compound identified by the Laboratory for Drug Discovery 
in Neurodegeneration (LDDN) and the Androphy Laboratory in the University of Indiana 
through screening in the SMN-luciferase reporter assay. LDN-75654, increases the stability of 
the SMN protein post-translationally, as proved by testing in the presence of SMN in SMA 
derived fibroblasts13. Although this compound had properties suitable for blood-brain-barrier 
penetration, it was established to be inactive in vivo, due to poor aqueous solubility and lack of 
metabolic stability. This small molecule, although inactive in vivo, presented an interesting 









Figure 2 Structure and activity of LDN-75654 on the SMN2- luciferase 
 
Through a structure-relationship relationship (SAR) study, several changes were introduced to 








Figure 3 Hit compound and areas suitable for SAR study 
 
To avoid the cleavage of the amide linker in the in vivo experiments14, thus increasing the 
solubility of the compound, the amide was reversed, but the activity (LDN-16) (Figure 4) (EC50 
= 9.9 ± 0.8 µM, 188 ± 13) was significantly reduced. Replacing the isoxazole core with a 
thiazole core (LDN-27) increased the activity in the SMN-luciferase reporter assay. 
 
 
Figure 4 Optimization results from SAR 
 
A number of different heterocycles were tested as analogues with the optimization of the hit 
compound to improve its potency, pharmacokinetic properties, and plasma stability by a 
structure-activity relationship (SAR) study. This resulted in the lead compound LDN-27 (EC50 




Figure 2 Activity of LDN-27 on the SMN-luciferase reporter assay 
 
1.4 Aim of study 
 
The aim of this project is to develop new analogues for the treatment of SMA by post 
translationally stabilizing the SMN protein with an imidazole core as the heterocycle, and to 
study its effect of the activity by means of the SMN-luciferase reporter assay as compared to 
the lead compound LDN-27. 
An array of different substituents attached to the phenyl core in conjunction to various 
substituents to the imidazole core will be examined to observe the impact on the activity.  
The imidazole ring proposed in this study is a possible heterocycle core that could improve the 
activity of the previous analogues. The imidazole ring is an aromatic five-member ring with 
two nitrogen atoms in the 1st and 3rd positions, and is present in many biologically active 
compounds, such as histidine and purine. Being a polar and ionisable aromatic ring, it can be 
used to improve the solubility and bioavailability of the previous poorly soluble lead 
compounds. It has amphoteric properties and the ability to form weak interactions15. 
It is widely used in the pharmaceutical industry in synthetic drugs due to the high therapeutic 
properties16 it possesses, such as anticancer, anticoagulant, anti-inflammatory, anti-bacterial, 
antifungal, antiviral and analgesic properties, among others. 
































2 THEORY AND METHODS 
 
2.1 N-Butyl lithium reaction 
 
Organometallic lithium reagents are strong nucleophilic bases, with high reactivities due to the 
polarity of the metal-carbon bond, in presence of water subtracts a hydrogen to form the 
corresponding hydrocarbon and lithium hydroxide (weak acid). The disadvantages of the 
organometallic reagents are the necessity of using very low temperatures (0 to -78º C) to avoid 
the undesired competitive reactions and the use of anhydrous solvents and inert atmosphere to 
avoid its degradation, which can react violently with air or moisture17. 
This type of reagent is used for many different applications such as for the synthesis of tertiary 
alcohols by a carbon-carbon bond forming reaction from ketones18, and its application is of 
interest for this project. 
The n-BuLi reacts with the imidazole ring to form and imidazole lithium complex in the first 
step of the mechanism. 
In the second step of the mechanism, the organometallic lithium complex acts as a nucleophile 
attacking the electrophilic carbon of the cyclobutanone, forming the corresponding alcohol 
once the reaction mixture is quenched with acid water, a saturated solution of ammonium 
chloride. 
Nucleophilic attack of the carbanionic carbon in the organometallic reagent with the 
electrophilic carbon in the carbonyl to form alcohols. 
 
 
Scheme 3 n-BuLi reaction mechanism 
 
 
2.2 Trimethylaluminum mediated amide coupling  
 
The usual aminolysis starting from carboxylic esters procedure is a three-step sequence 
involving hydrolysis, carboxylic acid activation and treatment with an amine. Although 
possible, the direct conversion of amines and esters to carboxamides was limited by harsh 
conditions and long reaction times until the report, in 1977, by Weinreb et al, of the utilization 
of trimethylaluminum amides to yield the desired aminolysis under mild reaction conditions19-
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20, making possible to avoid the three-step sequence. Trimethylaluminum (Me3Al) is a Lewis 
acid that promotes the activation of electronegative atoms, such as nitrogen and the 
nucleophilic substitution reactions21.  
The nitrogen on the aniline acts like a Llewis base that reacts at 0º C with trimethylaluminium 
with evolution of methane forming a dimethylaluminum amide complex [Scheme 4], which is 
unstable at high temperatures and further reacts with the carboxylic ester group while gently 
warming up to room temperature (RT) for 2h. The aluminium complex formed is quenched 
with a phosphate buffer that precipitates Aluminium phosphate (AlPO4) and is filtered out.  
The disadvantages of this reaction are the handling of trimethylaluminum that is highly 
pyrophoric and the competition between functional groups like carboxylic acids or nitriles with 
the carboxylic ester. 
 
 
Scheme 4 Proposed mechanism for the trimethylaluminum promoted aminolysis 
 
 
2.3 Nuclear Magnetic Resonance Spectroscopy  
 
Nuclear magnetic resonance (NMR) spectroscopy is one of the most useful techniques for 
structure determination in organic compounds as it provides a carbon-hydrogen framework of 
the molecule.  
This technique is based on the atoms that have isotopes with a characteristic nuclear spin (I) 
quantum number I = ½ such as 1H and 13C. In presence of an external magnetic field B0 the 
spin gets orientated creating two different energy levels proportional to ±I. 
In the absence of a magnetic field, the spin of the nuclei is randomly oriented, but when an 
external magnetic field B0 the nuclei spins orientate into determined positions, parallel or 
antiparallel to the magnetic field that have different energy levels. 
If the oriented nuclei are irradiated by energy with the right frequency that follows the 
resonance condition, the nuclei spins absorb enough energy to reverse their spin orientation.  
In so doing the nuclei reach a higher energy state. To have an NMR signal a difference in 
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population between the levels must exist and the intensity of the signal depends upon the size 
of the difference in population22. 
The magnet is a vital part of the NMR spectrometer, and it is directly related to the quality of 
the experimental measurement and the final spectrum. In modern instruments, the magnetic 
field B0 is directed along the axis of the sample tube. 
The probe-head of the NMR spectrometer contains the sample, its formed by the transmitter 
and receiver coils. The transmitter provides the various frequencies needed for the NMR 
experiment by means of a radiofrequency and a frequency synthesizer. It also produces the 
pulses required for the NMR experiment. The receiver collects the radiofrequency voltage 
corresponding to the energy of the NMR transition. After the signal is received, the signal must 
be amplified and processed by the computer. 
 
 
2.4 Mass Spectrometry 
 
Mass Spectrometry is an analytical technique used to determine the molecular weight of a 
molecule and to obtain structural information of the structure by measuring the molecular 
weight of the fragments produced when the molecule is irradiated with energy. It is a 
destructive technique, and it differs from other spectral analysis because the sample does not 
absorb radiation from the electromagnetic spectrum. Only small amounts of a sample are 
necessary due to the high sensitivity of the technique. 
Every mass spectrometer has three basic parts, regardless of the intended use for it [Scheme 4, 
Figure 3]. An ionization source, in which the sample is bombarded with a stream of high-
energy electrons that produces the dislodging of a valence electron form the molecule forming 
a radical cation [Scheme 5], that leads to the fragmentation of the molecule. A part of the 
fragments keeps the positive charge formed by losing an electron, the rest of the fragments 








Figure 3 General scheme of a mass spectrometer 
 
 
Scheme 6 Formation of the radical cation 
 
A mass analyzer, in which the different fragment ions formed are separated by their mass to 
charge ratio m/z. A strong magnetic field is applied to a curved chamber in which the neutral 
fragments are lost on the walls and the charged fragments are deflected into different paths 
depending on their m/z. For this project the mass analyzer utilized for both LC-MS and GC-
MS was a triple quadrupole. 
The triple quadrupole analyzer consists of four parallel metal rods that transmit varying radio 
frequency voltages along the axis of the rods in order to scan a range of different m/z values. 
The quadrupole can also be set to monitor a specific m/z value. When using a triple quadrupole 
different operational mode can be set depending on the application, a particularly interesting 
configuration is obtained when a combination cell is placed in between two mass analyzers, in 
which two stages of mass analysis are independently applied. This combination increases the 
sensitivity of the analysis over single stage mass analysis. 
 
 




And finally, a detector in which the ions are counted and recorded into peaks23-24.  
 
2.4.1 Liquid Chromatography Mass Spectrometry 
 
A chromatography technique is used to separate mixtures of compounds into individual 
components. By coupling chromatography with mass spectrometry every component of the 
analyte sample can be separated and evaluated individually. The main difference about the LC-
MS and GC-MS is the mobile phase used, in liquid chromatography mass spectrometry (LC-
MS) the mobile phase is a solvent. 
The coupling of liquid chromatography with mass spectrometry was limited by the 
incompatibility of ionization source with a liquid stream of the sample until the development 
of the electro spray ionization (ESI) source in the 1980s25-27. That is the same ionization source 
used for the analysis during this project. 
ESI is a robust ionization method that operated under atmospheric pressure and is based on the 
nebulizer-principle as a soft ionization due to the fact that little energy is imparted to the analyte 
that cause little fragmentation. In the chamber there is a difference of potential between the tip 
of the nebulizing needle and the orifice of the dielectric capillary [Figure 5]. The difference of 
potential produces a pointed cone of the sample solution, known as the Taylor cone, from where 
a spray of charged droplets are emitted. A drying gas, normally nitrogen (N2) evaporates the 
solvent until the solvated ions are expelled from the droplet and passed to the m/z analyzer. 
This method works well for non-volatile, thermally labile polar molecules and can be operated 
in order to detect both positive and negative ions. 
 
 




2.4.2 Gas Chromatography Mass Spectrometry 
 
As mentioned previously the main difference between GC-MS and LC-MS is the mobile phase 
used, in this case the mobile phase is an inert gas such as nitrogen. The mobile phase carries 
the sample through the stationary phase in which all the components from the sample interact 
and elute at different rates, hence the separation of the components.  
As the individual components elute from the GC column, they enter the ionization source. In 
this case the ionization source is electron impact (EI) [Figure 6], in which the analyte is 
bombarded with a high-energy electron beam producing the formation of the radical cation that 
further breaks into fragments [Scheme 7], some retaining charge some with neutral charge. 
 
Scheme 7 Formation of the radical cation 
 
 
Figure 6 EI 
 
 
In contrast to the little fragmentation observed by LC-MS ESI, the fragmentation observed by 
GC-MS EI is more extensive, and creates a spectral pattern that can be helpful for the 
identification of chemicals by comparing the spectral data with a mass spectra library. 
This ionization method is useful to analyze non-polar insoluble samples that are volatile and 




2.5 High Performance Liquid Chromatography 
 
High performance liquid chromatography (HPLC) is a modern liquid chromatography 
technique able to separate and quantify, with high sensitivity, compounds in a mixture based 
on the retention time using operational pressures higher than the pressures used for ordinary 
liquid chromatography. More efficient separations are achieved by using a stationary phase 
consisting on small particles28. 
It is the method used for the separation of non-volatile, very polar and ionic compounds with 




2.6 SMN2 – Luciferase Reporter Assay 
 
The testing for the increase of SMN protein was done by means of the second generation SMN-
luciferase reporter assay developed by Androphy and co-workers that combines the strengths 
of both previous assays, a promoter-based assay and a splicing reporter. Making the assay more 
robust, with lower variation and more stable luciferase expression12,13. 
 
The activity was confirmed in the SMN-luciferase cell line and counter-screened with a control 
cell line expressing luciferase. Good potency, strength of activation, dose dependency and 
favourable chemical properties should be over >60%. For a good compound the increase in 
luciferase activity should be over 100% and increase the control reporter cell line by less than 
40 %. The testing was done by dose response experiments, increasing concentration values 
from 0.04 to 30 µM. The average potency denoted as EC50, concentration required in order to 
achieve the 50% of the maximal drug response and Emax, indicates the maximal % increase in 




2.7 Positron Emission Tomography 3D Scan 
 
Nuclear functional imaging technique used to observe metabolic processes in the body. The 
system detects gamma rays emitted by a positron emitting radioligand. 
The development of positron emission tomography (PET) during the 1930s made possible the 
idea of in vivo measurement of biological or biochemical processes by producing radionuclides 
of chemical elements including carbon and fluoride that decay under positron emission, also 
known as positive beta decay, that is radiation externally detectable. PET employs short-lived 
positron emitting radionucleotides such as 11C (t1/2 = 20 min), 
13N (t1/2 = 10 min) and 
18F (t1/2 = 
110 min)29, that can take the place of other non-radioactive atoms in an active molecule that 
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bind to receptors or other sites of drug action, this type of molecules are called radioactive 
tracers. 
Due to the short half-life of the positron-emitting radioisotopes, the tracers tend to be produced 
in a cyclotron close to the PET facility. For this project the radiolabelling reaction was tested 
on an Agilent Technology 1260 Infinity with a LabLogic Radio-HPLC detector Posi-RAM 
model 4. The radionuclide was obtained by reducing radioactive carbon dioxide (CO2) and 






















3 RESULTS AND DISCUSSION 
 
3.1 Synthesis of N-(3-chloro-4-fluorophenyl)-2-(1-hydroxycyclobutyl)-1-methyl-
1H-imidazole-5-carboxamide (4) and other analogues 
 
3.1.1 Optimization of the N-BuLi reaction for the synthesis of Methyl 2-(1-
hydroxycyclobutyl)-1-methyl-1H-imidazole-5-carboxylate (1) 
 
In order to attach cyclobutanone to the second position of the imidazole ring using n-utyl 
lithium (N-BuLi) several experiments were carried with different conditions in order to 
optimize the reaction and achieve the highest yield possible [Table 1]. Methyl 1-methyl-1H-
imidazole-5-carboxylate was dissolved in anhydrous tetrahydrofuran THF and cooled down to 
-78º C or -40º C with a dry ice/acetone bath. N-BuLi was added drop-wise over a period of 15 
minutes. Cyclobutanone was added either before the N-BuLi or after 45 minutes depending on 
the conditions. The reaction mixture was quenched with ammonium chloride to yield methyl 
2-(1-hydroxycyclobutyl)-1-methyl-1H-imidazole-5-carboxylate 1 [Scheme 9]. 
 
 
Scheme 9 Synthesis of methyl 2-(1-hydroxycyclobutyl)-1-methyl-1H-imidazole-5-carboxylate (1) 
 
Exp T (º C) t Eq Add of 
cyclo 
Base Yield (%) 
379-12 -78º C 30 min/ 
ON 
















379-15 -40º C 30 min/ 
45 min 
1.3 2nd step n-BuLi 1.32 % 
379-16 -78º C 10min/ 
45 min 
1.3 2nd step n-BuLi 8.29 % 
379-17 -78º C 45 min 1.3 1st step n-BuLi 35.83 % 
379-19 -78º C 45 min 2 1st step n-BuLi 46.96 % 
379-26 -78º C 45 min 2.5 1st step n-BuLi 42.08 % 
 
Table 1 Overview of the contions used  for the optimization and symthesis of 1 
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Based on the yields obtained from this series of reactions the optimal conditions for the N-BuLi 
for the synthesis of 1 were adding cyclobutanone before 2 equivalents of n-BuLi were added 
drop-wise at - 78º C for 45 minutes. 
 
The 1H NMR spectrum of the product confirms the structure of the molecule with the only 
aromatic proton appearing in the most downfield part of the spectrum at 7.53 ppm, the proton 
corresponding to the hydroxy group appearing at 5.98 ppm and the six protons corresponding 
to the cyclobutyl appearing in the most upfield region of the spectrum [Figure 7]. The synthesis 
of the compound 1 was also confirmed by LC-MS [Anexe]. 
 
 
Figure 7 1H NMR spectrum of 1 
 
3.1.2 Methyl 2-(1-hydroxyethyl)-1-methyl-1H-imidazole-5-carboxylate (2) 
 
After the optimal conditions for the synthesis of methyl 2-(1-hydroxycyclobutyl)-1-methyl-
1H-imidazole-5-carboxylate were achieved, the same reaction conditions were used for the 






Scheme 10 Synthesis of methyl 2-(1-hydroxyethyl)-1-methyl-1H-imidazole-5-carboxylate (2) 
 
Based on the difference on the isolated yield, the conditions for the synthesis of 2 might need 
to be optimized in order to obtain a similar yield as the one obtained for 1 [Table 2].  
 











Table 2 Comparation of yisolated yields for 1 and 2 
 
The structure of the compound 2 was confirmed by 1H NMR spectroscopy with the sole 
aromatic proton of the Imidazole core appearing at 7.53 ppm in the most downfield region of 
the spectrum and the proton of the hydroxy substituent on the 2nd position appearing at 5.43 





Figure 8 1H NMR spectrum of 2 
 
3.1.3 Methyl 1-cyclobutyl-1H-imidazole-5-carboxylate (3) 
 
Methyl 1H-imidazole-5-carboxylate and caesium carbonate were dissolved in DMF, 
bromocyclobutane was added dropwise and stirred overnight to yield methyl 1-cyclobutyl-1H-
imidazole-5-carboxylate (3) [Scheme 11]. 
 
 
Scheme 11 Synthesis of methyl 1-cyclobutyl-1H-imidazole-5-carboxylate (3) 
 
The main difference between the 1H NMR spectrum for the compound 3 and the spectra for 1 
and 2 is the presence of a second more deshielded aromatic proton due to the lack of a 









carboxamide (4) and analogues 
 
A series of different analogues were synthesised by using the aminolysis procedure [Scheme 
12]. The corresponding aniline was dissolved in dry DCM and cooled down to 0º C, 
trimethylaluminum, under inert atmosphere to avoid a violent reaction with air and moisture, 
was added dropwise and stirred for an hour. The corresponding methyl carboxylate solution 
was added dropwise and stirred for two hours to yield the desired analogue.   
 
 




Table 3 summarises the eight reactions used for the synthesis of the different analogues 































































   
 
 86.24% 
Table 3 Overview of the synthesis of compounds 4 to 11 
 
The compounds 4-11 were analyzed by means of 1H NMR spectrometry and LC-MS. The 1H 
NMR spectrum of the compound 4 [Figure 10] shows the proton attached to the amide nitrogen 
in the most downfield part of the spectrum at 10.16 ppm, the only aromatic proton at the 4th 
position of the imidazole core appears at 7.66 ppm and the proton of the hydroxy group appears 




Figure 10 1H NMR spectrum of compound 4 
 
 
The 1H NMR spectrum of the compound 5 [Figure 11] shows the aromatic proton at the 4th 
position of the imidazole core appears at 7.66 ppm. The proton attached to the carbon on the 





Figure 11 1H NMR spectrum of compound 5 
 
 
The proton attached to the nitrogen atom on the amide group in the 1H NMR spectrum for the 
compound 6 appears at the downfield region of the spectrum at 10.10 ppm. Both of the aromatic 
protons of the imidazole cycle appear at 8.02 and 7.91 ppm. The protons of the cyclobutyl 
substituent appear in the upfield region of the spectrum in three multiplets, being the proton 




Figure 12 1H NMR spectrum of compound 6 
 
 
The 1H NMR spectra for the compounds 7 and 8 are significantly simpler than the rest due to 
the lack of a cyclic substituent in the 2nd position of the imidazole ring. The 1H NMR spectrum 
for compound 7 shows all the aromatic protons corresponding for both the phenyl and 
imidazole rings, 7.79 and 7.75 ppm for the imidazole aromatic protons. The three protons of 






Figure 13 1H NMR spectrum of compound 7 
 
 
The 1H NMR spectrum for compound 8 is very similar for that of the compound 7. All the 
protons of the compound appear in the aromatic region of the spectrum with the protons of the 





Figure 14 1H NMR spectrum of compound 8 
 
 
The 1H NMR spectrum for compound 9 is the first one of the analogues to not have the two 
halogen substituents in the phenyl ring, due to this the main difference from compound 4 is in 
the aromatic region. The aromatic proton from the imidazole core appears as a singlet at 7.64 
ppm, the six aromatic protons appear combined in three multiplets at 7.63-7.61, 7.35-7.31 and 





Figure 15 1H NMR spectrum of compound 9 
 
 
The main difference between the 1H NMR spectra for compound 4 and 10 is once again the 
aromatic region. For compound 10 the proton of the imidazole ring appears at 7.63 ppm and 
the four aromatic protons from the phenyl ring appear combined in two multiplets at 7.65-7.61 




Figure 16 1H NMR spectrum of compound 10 
 
 
Compound 11 was used without further purification for a following reaction. The 1H NMR 
spectrum shows some unidentified impurities in the upfield region of the spectrum. The 
aromatic proton of the imidazole ring appears as a singlet at 7.61 ppm. The protons for both 





Figure 17 1H NMR spectrum of compound 11 
 
 
Compounds 4 to 10 were tested for stabilization of the SMN protein in mice on the SMN-
luciferase reporter assay previously mentioned, this reporter assay was used as well for the 
previous hit compounds obtained by the SAR study. The objective of this project was to 
increase the activity and potency of the previous analogues by introducing a core which was 
not tested before. Study of a series of very similar analogues and the effect of those small 
differences for the activity. 
Curves for each tested compound were generated to determine EC50 values and percentage 
increase with a maximal concentration of 30 µM. Each compound was tested on two separate 
occasions and the values reported are the average of those experiments.  
A compound is considered inactive when the SMN-luciferase percentage induction is less than 
150% and EC50 is less than 1 µM. % needs to be as high as possible, EC50 has to be as low as 
possible. 
For compounds 4 to 8 most of the scaffold was kept constant and the substituents on the 1st and 
2nd positions of the imidazole ring were modified.  
Compound 4 is the most similar structure to the original hit compounds, having the orientation 
of the amide linker as LDN-75654 and the same heterocycle substituent as LDN-27. In this 
case the average Emax is 227.05% is higher than activation percentage for the previous hit 
compounds. The average value of EC50 = 3.35 µM is as well higher than the values for the hit 
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compounds, both of values indicate that the compound is active for the stabilization of SMN 
on the reporter assay however is not as active as the hit compounds [Figure 18]. 
 
 
Figure 18 Activation of the SMN-Luciferase reporter assay of 4 
 
 
The difference between 4 and 5 resides in the substituent of 2nd position of the imidazole ring. 
The value of Emax 5 is 22.95%, since it is lower than 100% the compound it is not active [Figure 
19]. The disparity between results indicate that the presence of a cyclic substituent might be 
significant for the stabilization. 
 
 




In the case of 6 the value of Emax = 126.9 % indicates some activity, however the value of EC50 
and the graph indicate that the compound is not active [Figure 20]. This result might indicate 









For the case of 7 the lack of a substituent on the 2nd position reduces the activity almost 
completely. Emax = 16.65% [Figure 21]. 
 
 




Surprisingly, the value Emax= 123 % is higher than expected for 8, the lack of substituents made 
the compound somewhat active but not enough active to become a new lead [Figure 22].  
 




9 and 10 have different substituents on the phenyl ring while keeping the rest of the structure 
as 4. For 9 the value Emax= 83.3 % [Figure 23] is too low to be considered active for the 
stabilization of the SMN protein. 
 
 
Figure 23 Activation of the SMN-Luciferase reporter assay of 9 
 
 
In the case of 10 the presence of the fluoro substituent gives a slightly higher value Emax= 
100.25% than the previous analogue while still being much more inactive than 4 [Figure 24]. 
This align with the result from the previous SAR in which the halogen atoms seem to be 
necessary for the activity of this series of small molecules. 
 
 













These same reaction conditions that were optimized for the synthesis of 1 were used for the 
synthesis of 12 [Scheme 13]. 
Methyl 1-methyl-1H-imidazole-4-carboxylate was dried overnight, dissolved in dry THF and 
cooled down to -78º C. Cyclobutanone was added to the reaction mixture. N-BuLi was added 
dropwise over a period of 15 min. The reaction mixture was stirred at -78º C for 45 min yielding 
methyl 2-(1-hydroxycyclobutyl)-1-methyl-1H-imidazole-4-carboxylate (12). 
 
 
Scheme 13 Synthesis of 12 
 
Compound 12 was used without further purification for the synthesis of compound 13. The 
same procedure as for the synthesis of compounds 4-11 was used. 3-Chloro-4-fluoroaniline 
was dissolved in dry DCM and trimethylaluminum was added dropwise and stirred for an hour 
at 0º C.  12 was added dropwise to the reaction mixture and stirred for 2 hours at RT to yield 
compound 13 [Scheme 14]. 
 
Scheme 14 Reaction scheme for the synthesis of 13 
 
The 1H NMR spectrum of compound 13 shows the aromatic proton of the imidazole ring in the 
downfield region of the spectrum at 7.72 ppm. The methyl on the 1st position of the imidazole 
ring appears slightly deshielded at 3.78 ppm due to being linked to a nitrogen. The protons 





Figure 25 1H NMR spectrum of compound 13 
 
The result of Emax= 59.15% and EC50 value indicate that 13 is not active for the stabilization of 
the SMN protein. This result compared to the values of 4 indicates the effect of the position of 
the amide linker has on the activity and potency [Figure 26]. 
 
 










After purification of 11 it was further treated with boron tribromide (BBr3) overnight at 0º C 
for the demethylation of the methyl ether in the para position of the aryl group to yield 2-(1-
hydroxycyclobutyl)-N-(4-hydroxyphenyl)-1-methyl-1H-imidazole-5-carboxamide 14 
[Scheme 15].  
 
 
Scheme 15 Reaction scheme for the synthesis of 14 
 
The formation of 14 by this procedure was confirmed by 1H NMR spectroscopy [Figure 27], 
some unknown impurities appear in the aromatic region of the spectrum. The hydroxyl group 
attached to the phenyl ring appears in the downfield part of the spectrum at 9.28 ppm, the 
amide proton appears in that same region at 9.86 ppm. The only free proton of the imidazole 
ring appears in the aromatic region at 7.66 ppm. The second hydroxy group of the molecule 
attached to the cyclobutyl substituent appears in the spectrum as a singlet at 5.99 ppm.  
 
 










Compound 4 was treated with sodium hydride and methyl iodide in order to methylate the 
nitrogen of the amide linker and to test the conditions for a possible cold lab reaction for the 
radiolabelling reaction. The reaction was tested first at 0º C during 1 hour [Scheme 16]. 
 
 
Scheme 16 Reaction scheme for the cold lab synthesis of 15 
 
The 1H NMR spectrum of compound 15 shows the proton of the hydroxy group at 6.32 ppm. 
For the 1H NMR spectrum of the compound 4 the proton linked to the nitrogen of the amide 
linker appears in the downfield region of the spectrum, in the spectrum for 15 that peak is 
missing and additional singlet for the protons of a methyl substituent appear at 3.85 ppm 






Figure 28 1H NMR spectrum of compound 15 
 
The result of the SMN-luciferase reporter assay for 15 follows the tendency observed in the 
previous SAR work in which N-methylation of the amide nitrogen makes the molecule inactive, 
Emax= 0% [Figure 29]. 
 
 
Figure 29 Activation of the SMN-Luciferase reporter assay of 15 
 
In a hot lab a similar reaction was tested for the potential radiolabelling of 4 following the 





Scheme 17 Radiolabelling reaction of 4 
 
4 was analysed by HPLC UV with a radioactivity detector in order to figure out the retention 
time of the reaction precursor before the radiolabelling reaction [Figure 30]. The retention time 
for 4 is 13:47. 
 
 
Figure 30 UV chromatogram of 4 as the radiolabelling precursor 
 
15 was also tested to get the retention time as the cold standard in order to analyse its retention 
time and be able to compare it to the retention time of the hot sample after the radiolabelling 




Figure 31 UV chromatogram of 15 (cold standard) 
 
Both cold samples of 4 and 15 were run together to evaluate the good separation between both 
compounds [Figure 32]. The peak of 15 appears labelled as Region 1 in the chromatogram and 
the peak of 4 appears as Region 2. 
 
 
Figure 32 UV chromatogram of the mixture of 4 and 15 
 
 
The UV chromatogram of the product of the radiolabelling reaction [Figure 33] shows only a 




Figure 33 UV chromatogram of the hot radiolabelling reaction 
 
However, the chromatogram of the hot run for the same sample does show a small peak of 
radioactivity with the retention time 12:50 [Figure 34]. Comparing this peak with the 
chromatogram and time of retention of the cold standard [Figure 31] the radiolabelling 
methylation reaction was successful with the conditions used. The disparity on the UV 
chromatogram [Figure 33] is due to the difference in concentration between the precursor 4 
and the radiolabelled compound. 
 
 





3.5 Other aminolysis procedures 
 
The most utilized procedures for the synthesis of amides consist of a nucleophilic acyl 
substitution reaction in which a nucleophile, an amine in this case, displaces the leaving group 
of the carboxylic acid derivative in a reaction known as aminolysis. 
The first procedure used for the synthesis of 4 was based on the reaction described by Drageset 
et al30 for the one pot amidation reaction in which the corresponding amide reacts with thionyl 
chloride to form iminosulfanone to further react with a carboxylic acid to yield the desired 
amide. The first attempt of this reaction was done using methyl 2-(1-hydroxycyclobutyl)-1-
methyl-1H-imidazole-5-carboxylate instead of the corresponding acid [Scheme 18]. The 
carboxylate was dissolved along with 3-chloro-4-flouroaniline and triethylamine in DCM at 0º 
C. Thionyl chloride was added to the reaction mixture and it was stirred for 20 min. The crude 
of the reaction was analysed by GC-MS in which the target product was not present. 
 
 
Scheme 18 Reaction scheme for the first unsuccessful aminolysis  
 
To follow the literature of the amidation procedure 1 was hydrolysed to 2-(1-
hydroxycyclobutyl)-1-methyl-1H-imidazole-5-carboxylic acid (16) by stirring 1 overnight in a 
solution of sodium hydroxide in THF and methanol [Scheme 19]. The formation of the 
carboxylic acid was confirmed by means of LC-MS but it could not be isolated, and it was 
utilized in the following reaction without purification. 
 
 
Scheme 19 Reaction scheme of the hydrolysis of 1  
 
A trial for the aminolysis was carried on using pyridine as the base instead of triethylamine and 
thionyl chloride31-32 for the in-situ formation of the corresponding acid chloride. With a longer 
reaction time of 1 hour instead of the 20 minutes described in the literature [Scheme 20]. The 
product was analysed by means of LC-MS in which the m/z 324 u for the product was present 
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as a trace along with several by-products. The reaction was scaled up but the results could not 
be reproduced. 
 
Scheme 20 Reaction scheme for the aminolysis  
 
Other aminolysis procedures have been described in the literature using HATU derivatives 
such as HOAt, tend to increase the electrophility of the carbonyl centre, efficiency increased 
due to the neighbouring effect provided by the pyridine nitrogen33-34. 
 
For this procedure 2-(1-hydroxycyclobutyl)-1-methyl-1H-imidazole-5-carboxylic acid and 3-
chloro-4-fluoroaniline were dissolved in DMF. HOAt and EDC were added to the reaction 
mixture and it was stirred overnight at RT [Scheme 21]. As it occurred with the former reaction, 
4 was observed when analysed with LC-MS m/z 324 u but when the reaction was scaled up the 
target compound was not observed and only the starting materials were present. 
 
 
Scheme 21 Second procedured attempted for the aminolysis 
 
The reason for the aminolysis reactions not being successful might be the formation of a salt 
during the hydrolysis of 1. The salt might be interfering with the reagents in the following 
reaction avoiding the formation of the desired product.  
 
3.6 Synthesis of methyl 1-methyl-1H-imidazole-5-carboxylate (17) 
 
The starting material for the synthesis of 1 was attempted to be synthesised following several 
different O-methylation and N-methylation procedures. The first series of attempt was using as 
starting material 1H-imidazole-5-carboxylic acid with the purpose of methylating both the 
carboxylic acid to form an ester (17), as well as the free amino group from the imidazole ring. 
For the first attempt powder potassium hydroxide and 1H-imidazole-5-carboxylic acid were 
dissolved in acetone by means of an ultrasonic bath and cooled down to 0º C with and ice/water 
bath. MeI was added drop wise and the reaction mixture was stirred for 2h [Scheme 22]. The 
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Scheme 22 First attempt for the double methylation 
 
Following the previous reaction, sodium hydride was used as a base and DMF was used instead 
of acetone as the solvent. 1H-Imidazole-5-carboxylic acid and the base were dissolved in 
anhydrous DMF, cooled down to 0º C and stirred for 1h [Scheme 23]. The LC-MS analysis 
showed the presence of the product as well as a number of by-products.  
 
 
Scheme 23 Second attempt for the double methylation  
1-Methyl-1H-imidazole-5-carboxylic acid and sodium hydride were dissolved in DMF by 
means of an ultrasonic bath and cooled down to 0º C before adding MeI dropwise and left to 
react for an hour [Scheme 24]. The GC-MS showed the presence of the product along with the 
starting material [Figure 35]. However, in the NMR of the reaction product the solvent peaks 
of the DMF are present, 8.03, 2.95 and 2.88 ppm [Figure 36] even after drying overnight under 
high vacuum.  
 
 






Figure 35 GC-MS spectrum of the first attempt to methylate 
 
 
Figure 36 1H NMR spectrum of 17, DMF solvent peaks 
 
The last attempt was made by switching the base to potassium carbonate [Scheme 25], that was 
dissolved along with 1-methyl-1H-imidazole-5-carboxylic acid in acetone by means of an 
ultrasonic bath. MeI was added dropwise and the reaction was stirred at 0º C for 2h to yield 17. 
The GC-MS analysis confirmed that the reaction worked for the synthesis of 17 but not to full 
conversion [Figure 37].  
 
 










3.7 Functionalisation of the imidazole ring 
 
The functionalisation of the back bone of the imidazole ring in order to introduce different 
functional groups is one of the vital steps for the use of imidazole rings in the pharmaceutical 
industry. 
Sandtorv et al35 developed a method of functionalisation of the imidazole ring by introducing 
halogen atoms by means of N,N’-dihalogenated analogues of 5,5-dimethylhydantoin. These 
reagents can be used to synthesize mono-halogenated, di-halogenated or tri-halogenated 
imidazole after being activated with a catalytic amount of a strong mineral acid.  
For the mono-bromination the imidazole ring was dissolved in water and N,N’-dibromo-5,5-
dimethylhydantoin (DBH) was added as a solid in small portions followed by a few drops of 
sulphuric acid [Scheme 26] to yield 18. The reaction mixture was quenched with a NaOH 
solution and neutralized with acetic acid until pH 6. As it was described in the literature the 
product m/z 147 was contaminated with other impurities as shown by the LC-MS analysis 
[Figure 38].  
 
 







Figure 38 LC-MS spectrum of 18 
 
2,4,5-Tribromo-1H-imidazole (19) was synthesized by dissolving the imidazole ring in water, 
the DBH was added in one portion followed by the drop-wise addition of sulphuric acid 
[Scheme 27]. The reaction mixture was quenched with a NaOH solution and neutralized with 
acetic acid. The reaction mixture was cooled in the fridge until the product had precipitated. 




Scheme 27 Reaction scheme for the synthesis of 19 
 
 
Figure 39 LC-MS spectrum of 19 
 
For the synthesis of 4(5)-Iodo-1H-imidazole (21) a conventional procedure was utilized, 4,5-
diiodo-1H-imidazole (20) was synthesised by dissolving imidazole in NaOH solution. A 
solution of KI and I2 in water was added drop-wise. The reaction mixture was stirred overnight 





Scheme 28 Reaction scheme for the synthesis of 20 
 
The formation of 20 was confirmed by means of GC-MS analysis m/z 319 [Figure 40]. 
 
 
Figure 40 GC-MS spectrum of 20 
Selective dehalogenation of 20 to yield 4(5)-Iodo-1H-imidazole (21) was done by dissolving 
4,5-diiodo-1H-imidazole in a potassium sulphite solution with 30% ethanol, heating up to 84º 
C with reflux and it was stirred for 22h [Scheme 29]. 
 
 
Scheme 29 Reaction scheme for the selective dehalogenation of 20 to yield 21 
 
The product 21 was confirmed by GC-MS analysis m/z 194 [Figure 41] 
 
 
Figure 41 GC-MS spectrum of 21 
 
A similar procedure as was previously described for 18 and 19 was also used for the synthesis 
of 21. Imidazole and potassium iodide were dissolved in water while the reaction flask was 
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cooled to 0º C with an ice-bath and a NaOH solution was added. Sulphuric acid was added to 
DIH and the mixture was added drop-wise to the reaction mixture and it was neutralized with 
acetic acid to yield 4(5)-Iodo-1H-imidazole [Scheme 30]. GC-MS analysis revealed the 
formation of the desired product m/z 194 [Figure 42]. It was not further used. 
 
 
Scheme 30 Second method used for the synthesis of 21 
 
 
Figure 42 GC-MS spectrum of 21 synthesized by means of DIH 
 
 
N-Methylation of 18 was formed by dissolving the imidazole with potassium hydroxide in 
acetone by means of an ultrasonic bath. MeI was added dropwise and the reaction mixture was 
stirred at 0º C for two hours [Scheme 31] to yield 22. Confirmed by LC-MS analysis m/z 161 
[Figure 43]. 
 
Scheme 31 Reaction scheme for the synthesis of 22 
 
 




The same procedure was used for the N-methylation of 4(5)-iodo-1H-imidazole to yield 4-
iodo-1-methyl-1H-imidazole (23) [Scheme 32]. The analysis of GC-MS confirmed the 
formation of the product, and unknown impurity was also in the GC-chromatogram. 
 
 
Scheme 32 Reaction scheme for the synthesis of 23  
 
Cyclobutanone was attempted to be attached to the back bone of the imidazole by means of a 
Grignard reaction to yield 24. 23 was previously dried and dissolved in anhydrous THF and it 
was added dropwise to a round bottom flask containing magnesium, the reaction mixture was 
stirred for 30 min and cyclobutanone was added dropwise [Scheme 33]. The reaction mixture 
was stirred for 10 min at RT. The reaction crude was analysed by means of GC-MS, the 
spectrum revealed that the reaction was unsuccessful. The magnesium might have not been 
activated and consequently not react with 23. 
 
 
Scheme 33 Reaction scheme for the first attempt to synthesize 24 
 
 
To help with the activation of the magnesium, dibromoethane was added to the first step of the 
Grignard reaction while keeping the same conditions for the reaction [Scheme 34]. The crude 
was analysed by means of a GC-MS and the spectrum revealed that the reaction did not form 
the desired product. 
 
 




Since the previous reaction did not yield the desired product, butyl lithium was used for a 
lithium-halogen exchange instead. 23 was dissolved in anhydrous THF and n-BuLi was added 
drop-wise over a period of 15 min. The reaction mixture was stirred at -78º C during 45 min 
before adding cyclobutanone and stirred for 45 min [Scheme 35]. GC-MS was used to analyse 
the reaction mixture and unfortunately the desired product was not formed. 
 
 
Scheme 35 Reaction scheme for the lithium-halogen exchange to yield 24 
 
A different series of analogues of LDN-75654 was attempted to be synthesized starting by 
using 4-nitroimidazole as starting material in order to have the different substituents in other 
positions and study the effect on the activity by testing the analogues on the SMN-Luciferase 
reporter assay. 
To N-methylate 4-nitroimidazole it was dissolved along with powdered potassium hydroxide 
in acetone with the aid of an ultrasonic bath before adding MeI drop-wise while keeping the 
reaction mixture to 0º C with an ice bath for 90 min to yield 25 [Scheme 36]. The reaction 
mixture was analysed by LC-MS, the spectrum showed that the reaction was not complete since 
both the starting material m/z 112 and the target product m/z 128 appear [Figures 44 and 45].  
 
 
Scheme 36 Reaction scheme for the synthesis of 25 
 
 






Figure 45 LC-MS spectrum negative for 25 
 
The 1-methyl-4-nitro-1H-imidazole 25 synthesized in the previous reaction was attempted to 
be reduced by a mixture of cobalt sulphate and sodium borohydride as described in the 
literature36 [Scheme 37] to yield 26. The analysis of the reaction mixture by LC-MS showed 
the formation of a coupling product m/z 177 and unknown impurity m/z 199 [Figure 46]. 
 
 
Scheme 37 Reaction scheme for the synthesis of 26 
 
 
Figure 46 LC-MS spectrum of 26 
 
A different procedure was attempted for the reduction of 25 with palladium hydroxide 
(Pd(OH)2) over carbon with hydrogen gas to yield 26. The imidazole and the palladium 
hydroxide were dissolved in anhydrous methanol. A balloon of hydrogen was bobbled on the 
reaction mixture and the reaction was heated up to 52º C overnight [Scheme 38]. 





Scheme 38 Second attempt for the synthesis of 26 
 
In the search of the right procedure for the amidation reaction other paths were studied. 
Previous work done in the group described the possibility of the synthesis of an amide bond 
from an alcohol through a domino oxidative amidation followed by transamidation37 in which 
the hydroxy group forms an intermediate amide by reacting with the dichlorohidantoin DCH. 
The intermediate then further reacts with the corresponding secondary amide to yield the 
desired amide by transamidation. 
In order to follow this procedure, the carboxylic acid of 1-methyl-1H-imidazole-5-carboxylic 
acid must be reduced to the corresponding alcohol 27. One of the most common procedures 
used to reduce carboxylic acids to primary alcohols is by using lithium aluminium hydride as 
reducing agent. To a 1-methyl-1H-imidazole-5-carboxylic acid solution in anhydrous THF 
LiAlH4 was added drop-wise during a period of 10 min [Scheme 39]. After 1 h the reaction 
mixture was quenched with acid water. A GC-MS was used to analyse the reaction mixture, 
the target molecule was present along with the coupling product and the corresponding 
aldehyde as an intermediate of the reduction. 
 
 
Scheme 39 First attempt for the synthesis of 27 
 
A procedure for reducing carboxylic acids into alcohols by means of sodium borohydride 
NaBH4 and iodine I2
38-39 [Scheme 40]. The carboxylic acid solution in THF was added slowly 
to a suspension of NaBH4 in THF and stirred until gas is no longer be formed. A solution of I2 
in THF is then added slowly at RT, the reaction mixture was stirred for 1 h. The target 
compound was not accomplished by following this method. 
 
 
Scheme 40 Second attempt for the synthesis of 27 
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The primary aim of this project was to synthesize new analogues of the previously developed 
lead compounds, LDN-75654 and LDN-27, with the intent of improving the pharmacokinetic 
properties and activities reported for the post-translationally stabilization of the SMN protein 
for the treatment of SMA. The main target molecule originally designed for this project, 4, 
contained similarities to both lead compounds being the most substantial difference the 
imidazole ring as the heterocycle core of the molecule. A series of seven different analogues 
were developed by altering the substituents of the structure but maintaining the imidazole core 
and direction of the amide linker. One structural isomer, 13, was also developed in order to 
study the effect on the position of the substituents in the activity. 
The synthesis of the analogues was a two-step synthesis starting from a commercially available 
starting material, methyl 1-methyl-1H-imidazole-5-carboxylate for the majority of the 
analogues, treated with n-BuLi and the corresponding ketone or aldehyde at low temperature, 
following the trimethylaluminum mediated aminolysis.  
From the eleven analogues successfully developed, nine of them were tested by the SMN-
luciferase reporter assay to study the activity on the stabilization of the SMN protein. Although 
the only analogue presenting significant activity was 4, it did not improve the activities reported 
for the previous lead compounds, implying that the substituents optimized for LDN-27 by 
means of a SAR study are not ideal for the imidazole core-based analogues. 
4 was also used to test a radiolabelling reaction to obtain a radiolabelled version of 15. A good 
separation method and good reaction conditions were achieved and the desired hot sample was 
synthesized and analyzed.  
 
During this project a number of attempted reactions were not accomplished as desired. 
The synthesis of methyl 1-methyl-1H-imidazole-5-carboxylate, starting material for most of 
the analogues synthesised in this project, was attempted by four slightly different procedures 
without achieving a procedure that is reproducible and has good enough conversion to be used 
for the synthesis of the analogues. 
The synthesis of 24 was attempted following two different procedures, a Grignard reaction and 
a Lithium-halogen exchange, both reactions were unsuccessful and the desired target molecule 
was not accomplished. The starting materials, 22 and 23, were also synthesized following 
different procedures during this project.  
A different series of analogues based on 4-nitroimidazole was attempted. The first reaction 
using it as starting material to yield 25 after being methylated. Unfortunately, the two methods 
attempted to reduce the nitro group of 25 to yield 26 were not successful. The attempted 




4.2 Further work  
 
Based on the testing data obtained by the SMN-luciferase reported assay on the activity of the 
different analogues synthesized during this project it has been determined that the substituents 
previously optimized for the hit compound with the thiazole core are not as optimal for the 
imidazole core analogues. A new SAR study would be interesting for the imidazole core small 
molecules. Considering the activation of 4 on the reporter assay, the imidazole ring is still an 
interesting approach. 
The success on the radiolabelling attempted during this project presents an interest in 
developing and attempting similar radiolabelling reactions for the rest of the analogues as the 
starting point of a new project focused on developing a series of possible PET 3D scan tracers. 
 
A number of synthetic routes attempted during this project hold potential for improvement, 
such as the synthesis of 17 as the starting material for most of the analogues synthesized. A 
different set of reactions and conditions could be attempted to attempt the synthesis of the 
























Most of the chemicals used to synthesize the imidazole core analogues were purchased 
commercially and used as received. The exception is 1,3-diiodo-5,5-dimethylhydantoin (DIH) 
that was previously produced in the group by means of continuous flow. 
 
Experimental description 
TLC analyses were performed on coated aluminium foils embedded with fluorescent indicator 
254 nm or on glass. The mobile phase used consisted of various mixtures of hexane and ethyl 
acetate or dichloromethane and methanol. 
Manual flash chromatography was performed using silica gel as stationary phase. Automatic 
flash column chromatography was carried on a Teledyne isco combiflash rf column with Agela 
Flash Column Silica-CS 60 Å. 
 
Spectroscopic descriptions  
NMR spectra were obtained on a Bruker Biospin AV500 (500 MHz for 1H, 125 MHz for 
13C). Chemical shifts are reported in ppm relative to the signal of the remaining protons of the 
deuterated solvent used. Coupling constants are given in Hz and the multiplicity is reported as 
singlet (s), doublet (d), triplet (t), quartet (qt) and multiplet (m). 
 
GC-MS analyses were performed on a capillary gas chromatograph with a fused silica column 
and helium as the carrier gas. The gas chromatograph was connected to a mass spectrometer 
using electron ionisation (EI) as ionisation source. 
 
LC-MS and MS-MS analysis were performed on an Aglient 6420A triple quadrupole (QqQ 
configuration) mass analyser using electrospray ionisation (ESI). It is connected to an Agilent 
1200 series LC module (binary pump, column compartment/oven and autosampler). The 
column used was an Agilent ZORBAX SB-C18, RRHT; 2.1 x 50 mm x 1.8 m.  
Agilent 1260 Infinity Quaternary LC system interfaced to an Agilent 6120 Single Quadrupole 
mass spectrometer were also used for LC-MS analysis. 
 
HPLC purification was done with an Agilent 1260 Infinity II attached to a 6120 Quadrupole 
LC/MS. 
 
The radiolabelled sample of 15 was analyzed with an Agilent 1260 Infinity instrument attached 
to a Radio-HPLC detector Posi-RAM model 4 Lablogic with a Luna Omega 3 µm Polar C18 





Methyl 2-(1-hydroxycyclobutyl)-1-methyl-1H-imidazole-5-carboxylate 1: Methyl 1-methyl-
1H-imidazole-4-carboxylate (270.40 mg, 1.93mmol) was dried overnight on a desiccator and 
dissolved in dry THF (10 ml) and cooled to -78º C with a dry ice/acetone bath under nitrogen 
inert atmosphere. Cyclobutanone (270.48 mg, 0.290 mL, 3.86 mmol) was added to the reaction 
mixture. N-Buthyl lithium (n-BuLi) (247.19mg, 1.54mL, 2.5 M) was added dropwise during a 
period of 15 min. After 45 min the reaction mixture was quenched with a saturated ammonium 
chloride solution (NH4Cl) (20 ml), extracted with EtOAc (3x25 ml) and dried over magnesium 
sulphate. The purification was made by means of an autoflash column DCM: MeOH 95:5 to 
yield methyl 2-(1-hydroxycyclobutyl)-1-methyl-1H-imidazole-5-carboxylate (190.50mg, 
0.906 mmol, 46.96 % yield). 1H NMR (400 MHz, 25 ºC, DMSO) δ 7.54 (s, 1H), 5.98 (s, 1H), 
3.81 (s, 3H), 3.79 (s, 3H), 3.29 (s, 1H), 2.70 (m, 2H), 2.26 (m, 2H), 1.75 (m, 1H), 1.44 (m, 1H) 
ppm.  
 
The same procedure was used for the synthesis of methyl 2-(1-hydroxyethyl)-1-methyl-1H-
imidazole-5-carboxylate 2 (11.50 mg, 0.062 mmol, 22.08% yield). 1H NMR (400 MHz, 25 ºC, 
DMSO) δ 7.53 (s, 1H), 5.43 (d, 1H, J = 6.36 Hz), 4.85 (t, 1H, J = 6.36 Hz), 3.86 (s, 3H), 3.75 
(s, 3H), 1.46 (d, 3H, J = 6.36 Hz) ppm. 
 
Methyl 1-cyclobutyl-1H-imidazole-5-carboxylate 3: Methyl 1H-imidazole-5-carboxylate 
(248.20 mg, 1.97 mmol) and caesium carbonate (Cs2CO3) (1.28 g, 3.94 mmol) were dissolved 
in N,N-Dimethylformamide (DMF) (15 ml) and bromocyclobutane (292.26 mg, 0.203 ml, 2.16 
mmol) was added to the reaction mixture and it was stirred at RT overnight. H2O (20 ml) was 
added and the reaction mixture was extracted with EtOAc (3x30 ml) and dried over sodium 
sulphate. Purified by means of an autoflash column DCM: MeOH 95:5 to yield 4 (146.22 mg, 
1.97 mmol, 41.23% yield). 1H NMR (400 MHz, 25 ºC, DMSO) δ 8.17 (s, 1H), 7.63 (s, 1H), 
5.10 (q, 1H, J = 8.8 Hz), 3.29 (s, 1H), 2.48 (d, 2H, J = 1.96 Hz), 2.34 (m, 2H), 2.29 (m, 2H), 
1.76 (m, 2H) ppm. 
 
General procedure for the synthesis of 4-11. 3-Chloro-4-fluoroaniline was dissolved in dry 
DCM (2 ml) under inert atmosphere and cooled to 0º C with an ice/water bath. 
Trimethylaluminum (102.35 mg, 0.709 ml, 1.42 mmol) was added dropwise over a period of 
10 min and the reaction mixture was stirred for 1h. Methyl 2-(1-hydroxycyclobutyl)-1-methyl-
1H-imidazole-5-carboxylate (99.50 mg, 0.473 mmol) was dissolved in dry DCM (2 ml) and 
added dropwise over a period of 15 min to the previous reaction mixture and was stirred at RT 
for 2 h. Change colour to yellow. After the reaction time the reaction mixture was quenched 
with a phosphate buffer and stirred for 15 min, diluted in DCM and the aluminium salts filtered 
off. The filtrate was washed with H2O (3x25 ml) and dried over sodium sulphate. The 
purification of the title compound was done by autoflash column DCM:MeOH 95:5 to yield 
N-(3-chloro-4-fluorophenyl)-2-(1-hydroxycyclobutyl)-1-methyl-1H-imidazole-5-
carboxamide 4 (22.10 mg, 0.068 mmol, 14.42% yield). 1H NMR (400 MHz, 25 ºC, DMSO) δ 
10.16 (s, 1H), 7.98 (dd, 1H, J = 6.8, 2.4 Hz), 7.66 (s, 1H), 7.62 (m, 1H), 7.38 (t, 1H, J = 9 Hz), 
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5.95 (s, 1H), 3.29 (s, 3H), 2.73-2.69 (m, 2H), 2.27-2.22 (m, 2H), 1.78-1.74 (m, 1H), 1.48-1.45 
(m, 1H) ppm.      
N-(3-chloro-4-fluorophenyl)-2-(1-hydroxyethyl)-1-methyl-1H-imidazole-5-carboxamide 5: (4 
mg, 0.013 mmol, 16.72% yield) 1H NMR (400 MHz, 25 ºC, MeOH) δ 7.90 (dd, 1H, J = 6.0, 
2.7 Hz), 7.66 (s, 1H), 7.54 (m, 1H), 7.20 (t, 1H, J = 9 Hz), 5.01 (d, 1H, J = 6.36 Hz), 4.00 (s, 
3H), 1.61 (d, 3H, J = 6.36 Hz) ppm. 
N-(3-chloro-4-fluorophenyl)-1-cyclobutyl-1H-imidazole-5-carboxamide 6: (39.20 mg, 0.133 
mmol, 60.12% yield) 1H NMR (400 MHz, 25 ºC, DMSO) δ 10.10 (s, 1H), 8.14 (dd, 1H, J = 
6.8, 2.4 Hz), 8.02 (s, 1H), 7.91 (s, 1H), 7.78 (m, 1H), 7.34 (t, 1H, J = 9 Hz), 4.77 (q, 1H, J = 
8.8 Hz), 2.42-2.36 (m, 4H), 1.83-1.71 (m, 2H) ppm.  
N-(3-chloro-4-fluorophenyl)-1-methyl-1H-imidazole-5-carboxamide 7: (15.20 mg, 0.060 
mmol, 17.50% yield) 1H NMR (400 MHz, 25 ºC, MeOH) δ 7.90 (dd, 1H, J = 6.8, 2.5 Hz), 7.79 
(s, 1H), 7.75 (s, 1H), 7.54 (m, 1H), 7.20 (t, 1H, J = 9 Hz), 3.95 (s, 3H) ppm. 
N-(3-chloro-4-fluorophenyl)-1H-imidazole-5-carboxamide 8: (11.20 mg, 0.046 mmol, 5.89% 
yield) 1H NMR (400 MHz, 25 ºC, MeOH) δ 8.00-7.99 (m, 1H), 7.78 (m, 1H), 7.76 (s, 1H), 
7.56 (m, 1H), 7.23-7.19 (m, 1H) ppm. 
2-(1-hydroxycyclobutyl)-1-methyl-N-phenyl-1H-imidazole-5-carboxamide 9: (5.20 mg, 0.019 
mmol, 9.90% yield) 1H NMR (400 MHz, 25 ºC, MeOH) δ 7.64 (s, 1H), 7.63-7.61 (m, 2H), 
7.35-7.31 (m, 2H), 7.12-7.10 (m, 1H), 3.95 (s, 3H), 2.82-2-77 (m, 2H), 2.40-2.37 (m, 2H), 
2.00-1.93 (m, 1H), 1.68-1.65 (m, 1H) ppm.   
N-(4-fluorophenyl)-2-(1-hydroxycyclobutyl)-1-methyl-1H-imidazole-5-carboxamide 10: 
(4.60 mg, 0.016 mmol, 8.68% yield) 1H NMR (400 MHz, 25 ºC, MeOH) δ 7.65-7.61 (m, 2H), 
7.63 (s, 1H), 7.07 (t, 2H, J = 8.8 Hz), 3.95 (s, 3H), 2.83-2.77 (m, 2H), 2.40-2.37 (m, 2H), 1.92-
1.90 (m, 1H), 1.68-1.65 (m, 1H) ppm. 
2-(1-hydroxycyclobutyl)-N-(4-methoxyphenyl)-1-methyl-1H-imidazole-5-carboxamide 11: 
(64.90 mg, 0.215 mmol, 86.24% yield) 1H NMR (400 MHz, 25 ºC, MeOH) δ 7.61(s, 1H), 7.50 
(d, 2H, J = 8.8 Hz), 6.90 (d, 2H, J = 9.32 Hz), 3.94 (s, 3H), 3.79 (s, 3H), 2.82-2.80 (m, 2H), 
2.40-2.37 (m, 2H), 2.00-1.98 (m, 1H), 1.66-1.64 (m, 2H) ppm.  
Methyl 2-(1-hydroxycyclobutyl)-1-methyl-1H-imidazole-4-carboxylate 12: Similar procedure 
used as for the synthesis of 1. (153.20 mg, 0.728 mmol, 38.99% yield). It was further used 
without purification.  
N-(3-chloro-4-fluorophenyl)-2-(1-hydroxycyclobutyl)-1-methyl-1H-imidazole-4-
carboxamide 13: same procedure as for the synthesis of 4. (30.20 mg, 0.093 mmol, 12.80% 
yield) 1H NMR (400 MHz, 25 ºC, MeOH) δ 7.99-7.98 (m, 1H), 7.73 (s, 1H), 7.57 (m, 1H), 
7.21 (t, 1H, J = 9 Hz), 3.78 (s, 3H), 2.87-2-82 (m, 2H), 2.39-2.36 (m, 2H), 2.00-1.98 (m, 1H), 
1.93-1.70 (m, 1H) ppm.  
2-(1-hydroxycyclobutyl)-N-(4-hydroxyphenyl)-1-methyl-1H-imidazole-5-carboxamide 14: 12 
(59.70 mg, 0.198 mmol) was dissolved in DCM and cooled down to 0º C with and ice bath. 
Tribromo boron (BBr3) (54.59 mg, 0.218 ml, 0.218 mmol) was added dropwise over a period 
of 5 min. The reaction mixture was stirred overnight at 0º C. Water (20 ml) was added and 
extracted with a DCM:Isopropanol 90:10 (3x40 ml). The compound was purified by prep 
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HPLC. 1H NMR (400 MHz, 25 ºC, DMSO) δ 9.87 (s, 1H), 9.28 (s, 1H), 7.66 (s, 1H), 7.45 (d, 
2H, J = 8.94 Hz), 6.73 (d, 2H, J = 8.78 Hz), 5.99 (s, 1H), 3.84 (s, 3H), 2.74-2.72 (m, 2H), 2.37-
2.27 (m, 2H), 1.44-1.43 (m, 1H), 1.41-1.40 (m, 1H). 
N-(3-chloro-4-fluorophenyl)-2-(1-hydroxycyclobutyl)-N,1-dimethyl-1H-imidazole-5-
carboxamide 15: 3 (27.80 mg, 0.086 mmol) and sodium hydride (NaH) (3.43 mg, 0.086 mmol) 
were dissolved in dry THF (3 ml) and cooled down to 0º C. Methyl iodide (12.19 mg, 0.005 
ml, 0.086 mmol) was added dropwise over a 5 min period and the reaction mixture was stirred 
for 1.5 h at 0º C. The reaction mixture was quenched with water (15 ml) and extracted with 
EtOAc (3x25 ml) and dried over sodium sulphate. Purified by autoflash column 
chromatography DCM: MeOH 90:5 to yield the compound (16.90 mg, 0.050 mmol, 58.27% 
yield) 1H NMR (400 MHz, 25 ºC, MeOH) δ 7.52 (m, 1H), 7.28-7.26 (m, 1H), 6.32 (s, 1H), 
3.85 (s, 3H), 3.41 (s, 3H), 2.71-2.68 (m, 2H), 2.33-2.30 (m, 2H), 1.88-1.80 (m, 1H), 1.59-1.56 
(m,1H) ppm. 
This same procedure was used for the radiolabelling with 11C but at room temperature in a hot 
lab. 
 
For the synthesis of 2-(1-hydroxycyclobutyl)-1-methyl-1H-imidazole-5-carboxylic acid 16: 1 
(78.50 mg, 0.373 mmol) was hydrolysed by dissolving it in a 1:1 THF:MeOH (1 ml). A 1M 
NaOH solution (1.49 ml, 1.49 mmol) was added to the reaction mixture and it was stirred ON. 
The solvent was removed under reduced pressure, 16 was used without further purification or 
isolation.  
 
Several procedures were used for the synthesis of methyl 1-methyl-1H-imidazole-5-
carboxylate 17: The first one used for the methylation of 1H-imidazole-5-carboxylic acid (566 
mg, 5.05 mmol) was to dissolve it along KOH ( 374 mg, 6.65 mmol) in acetone (5 ml) by 
means of an ultrasonic bath, cooled down to 0º C with an ice/water bath. MeI (0.62 ml, 1.42 g, 
10 mmol) was added drop-wise and the reaction was stirred for 90 min. The reaction mixture 
was diluted with water (10 ml) and extracted with EtOAc (3 x 10 ml), dried over Na2SO4 and 
the solvent removed under reduced pressure. 
The second procedure used consisted in dissolving 1H-imidazole-5-carboxylic acid (0.53 g, 
4.77 mmol) and NaH (0.72 g, 30 mmol) on anhydrous DMF under inert atmosphere. Excess 
MeI (1.4 ml) was added drop-wise at 0º C. After 1h the reaction mixture was solid, water (10 
ml) was added to dissolve the reaction mixture, EtOAc (3 x 25 ml) was used to extract the 
reaction mixture, dried over Na2SO4 and the solvent reduced under pressure to yield an orange 
oil 17 (0.53 g, 3.80 mmol, 79.53% yield, contaminated with DMF). This same procedure was 
used to attempt the methylation of 1-methyl-1H-imidazole-5-carboxylic acid (0.92 g, 8.12 
mmol) with NaH (1.18 g, 49.03 mmol) and MeI (4.58 ml, 10.44 g, 73.55 mmol) to yield 17 
(0.87 g, 6.24 mmol, 85.96% yield contaminated with DMF). 
 
The last procedure used consisted in dissolving 1-methyl-1H-imidazole-5-carboxylic acid 
(0.25 g, 1.95 mmol) and K2CO3 (1.11 g, 8 mmol) in acetone (10 ml) with the aid of an ultrasonic 
bath. MeI (0.4 ml, 0.83 g, 5.85 mmol) was added drop-wise and the reaction mixture was stirred 
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at 0º C for 90 min. The reaction mixture was diluted with water (15 ml) and extracted with 
EtOAc (3 x 30 ml), dried over Na2SO4 and the solvent removed under reduced pressure. 
 
For the synthesis of 4-bromo-1H-imidazole 18: imidazole (0.08 g, 1.16 mmol) was dissolved 
in water (10 ml), DBH (0.10 g, 3.60 mmol) was added followed by H2SO4 (2 ml) in few 
portions. The reaction was quenched with NaOH (3.8 M, 20 ml) and neutralized with acetic 
acid until pH ~6. 1/3 of the solvent was evaporated under reduced pressure and the insoluble 
salts were filtered off. Enough NaCl was added in order to make a saturated solution and diethyl 
ether (3 x 30 ml) was used to extract the reaction mixture, dried over Na2SO4 and the solvent 
removed under reduced pressure to yield a white precipitate (0.058 g, 0.38 mmol, 33.5% yield 
contaminated with DBH). 
2,4,5-tribromo-1H-imidazole 19: was synthesized by dissolving imidazole (0.086 g, 1.26 
mmol) in water (10 ml), DBH (0.58 g, 2.04 mmol) was added in one portion to yield a yellow 
solution. H2SO4 (1 ml) was added drop-wise. A NaOH solution (3.8 M, 20 ml) was added to 
quench the reaction and the pH was adjusted until pH ~6 with acetic acid. The reaction mixture 
was kept in the fridge until complete precipitation of 19 (0.089mg, 0.3 mmol, 23.27% yield). 
 
To synthesize 4,5-diiodo-1H-imidazole 20: imidazole (11.09 g, 162.9 mmol) was dissolved in 
a NaOH solution (4 M, 600 ml). A separate solution was made of KI (147.2 g, 886.7 mmol) 
and I2 (88.18 g, 347.4 mmol) in water and it was added drop-wise to the imidazole solution. 
The reaction mixture was stirred for 20 h at RT. The reaction mixture was neutralized until the 
product precipitated with acetic acid. The crystals were washed with several portions of NaSO3 
and ice water. The product was not dried or purified further for the next reaction. 
 
4-iodo-1H-imidazole 21: was synthesized by two different procedures. The first one being the 
selective dehalogenation of 20 (21.75 g,68.01 mmol) for which it was dissolved in a 30% 
ethanol solution (400 ml) along with K2SO3 (187.4 g, 1183 mmol) and refluxed at 84º C for 
22h. The reaction mixture was cooled down to RT and the inorganic salts were filtered off. The 
ethanol was removed under reduced pressure and NaCl was added to make a saturated solution 
of the aqueous phase before being extracted with ether:THF (1:1) (3 x 300 ml), dried over 
Na2SO4 and the solvent was removed under reduced pressure. 
The second method used DIH for the synthesis of 21: Imidazole (411 mg, 6.04 mmol) was 
dissolved in water (50 ml) and cooled down to 0º C with an ice bath. A DIH solution (0.54 g, 
1.42 mmol) was made in sulfuric acid (5 ml) and the solution was added drop-wise to the 
imidazole solution. A NaOH solution (3.8 M, 50 ml) was added to the reaction mixture and the 
pH was adjusted to 6 with acetic acid. The reaction mixture was first extracted with ether (3 x 
40 ml) and then with a 10% HCl solution (3 x10 ml). The water was removed under reduced 
pressure and the product precipitated. The pH was adjusted to 6 with a sodium bicarbonate 
solution and extracted with ether (3 x 30 ml), the solvent was removed under reduced pressure 




Both 4-bromo-1-methyl-1H-imidazole 22 and 4-iodo-1-methyl-1H-imidazole 23 were 
synthesized by following one of the procedures attempted for the synthesis of 17. The 
corresponding imidazole and KOH were dissolved in acetone by means of an ultrasonic bath 
and cooled down to 0º C. Excess MeI was added drop-wise and the reaction mixture was stirred 
for 90 min. Water was added and the reaction mixture was extracted with EtOAc, dried over 
Na2SO4 and the solvent removed under reduced pressure to yield the corresponding product. 
22 (0.036g, 0.17 mmol, 36.87% yield), 23 (0.13 g, 0.62 mmol, 67.97% yield). 
 
23 was used to attempt the synthesis of 1-(1-methyl-1H-imidazol-4-yl)cyclobutan-1-ol 24 
using two different procedures, unfortunately neither of them yielded the desired product.  
For the first attempt a Grignard reaction was used. For this Mg (0.075 g, 3.10 mmol) was dried 
beforehand in a round bottle flask. Anhydrous THF (5 ml) was added to the flask. A solution 
of 23 (0.13 g, 0.62 mmol) in THF was added to the reaction flask and it was stirred for 30 min. 
Cyclobutanone (0.23 ml, 0.22 mg, 3.11 mmol) was added drop-wise. After 10 min a saturated 
solution of ammonium chloride (10 ml) was added and the reaction mixture was extracted with 
DCM (3 x 15 ml). No reaction occurred. 
For the second attempt of the Grignard reaction. Dibromoethane (0.14 ml, 0.30 g, 1.60 mmol) 
was added to the Mg solution in order to activate the Mg. After 10 min, the solution of 23 was 
added to the reaction flask. The rest of the procedure was the same. 
The second procedure used to attempt the synthesis of 24 was by lithium-halogen exchange. 
23 (0.15 g, 0.71 mmol) was dissolved in dry THF (10 ml), n-BuLi (0.56 ml, 1.41 mmol) was 
added drop-wise over a period of 10 min, the reaction mixture was stirred at -78º C for 45 min. 
Cyclobutanone (0.08 ml, 0.08 g, 1.14 mmol) was added and the reaction mixture was stirred 
for 45 min more. The reaction mixture was quenched with water (15 ml) and extracted with 
EtOAt (3 x 25 ml), dried over Na2SO4 and the solvent removed under reduced pressure. The 
desired product was not formed. 
 
1-methyl-4-nitro-1H-imidazole 25: 4-nitroimidazole (0.56 g, 5 mmol) and KOH (0.37 g, 6.65 
mmol) were dissolved in acetone (10 ml) by means of an ultrasonic bath and cooled down to 
0º C with an ice bath. MeI (0.33 ml, 0.76 g, 5.35 mmol) was added drop-wise. After 90 min 
water (10 ml) was added and was extracted with EtOAc (3 x 10 ml), dried over Na2SO4 and the 
solvent was removed under reduced pressure to yield 25 (0.13 g, 1.03 mmol, 20.61% yield). 
1-methyl-1H-imidazol-4-amine 26: Two different attempts to reduce the nitro group of 25 were 
tested. 
For the first one 25 (0.066 mg, 0.51 mmol) was dissolved in EtOH (5 ml). A solution of CoSO4 
(0.144 g, 0.51 mmol) was made in water (0.7 ml) and added drop-wise while cooling down to 
0º C with an ice bath. NaBH4 (0.077 mg, 2.04 mmol) was added in portions to the reaction 
mixture. The reaction mixture was stirred at RT for 10 min. The catalyst was filtered off and 
the reaction mixture was diluted with water (50 ml) and extracted with EtOAc (2 x 40 ml), 




The second reduction procedure to synthesize 26 consisted in dissolving 25 (0.11 g, 1.00 mmol) 
and Pd(OH)2/C (15% w/w) in dry DCM (25 ml), H2 was introduced to the reaction with a 
balloon, the reaction was heated at 52º C overnight. The palladium catalyst was filtered off 
with a celite filter and it was washed with methanol and water. The product was not obtained 
either by this method. 
(1-methyl-1H-imidazol-5-yl)methanol 27: To reduce the carboxylic group of 1-methyl-1H-
imidazole-5-carboxylic acid (0.11 g, 0.79 mmol) it was dissolved in dry THF (10 ml) under 
inert atmosphere. LiAlH4 (1.59 ml, 0.06 g, 1.59 mmol) was added and the reaction was stirred 
at 0º C during 1 h. Water (10 ml) was added while keeping the temperature at 0º C. The reaction 
mixture was extracted with EtOAc (3 x 25 ml), dried over Na2SO4 and the solvent was removed 
under reduced pressure. 27 was not obtained by following this procedure, only the coupling 
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LC-MS spectrum of 16 (fourth procedure) 
 
 
LC-MS spectrum of 19 
 
 
GC-MS spectrum of 20 
 




GC-MS spectrum for 21 (Second procedure) 
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LC-MS spectrum for 26 (first procedure) 
90 
 
 
 
 
